Dongwha Pharm

At a glance

Dongwha Pharm filed 28 disclosures in the last 12 months, including 2 5% holder. The most recent key filing was on Aug 11.

Revenue for 2025 was ₩496B, up 6.8% on 2024. Operating margin was 0.1% against 2.9% a year earlier. Debt was 60% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩268B and operating profit of ₩21.5B.

The 2025 annual report lists 838 employees with an average tenure of 12.7 years and average pay of ₩71.3M, #563 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩164M each on average. It paid ₩65 per common share in cash dividends, against ₩180 a year earlier (-63.9%). 디더블유피홀딩스(주) and related parties held 33.64% at year end.

From the 2025 annual report

Staff: 838 (613 men, 225 women), of whom 16 on fixed-term contracts. Total pay for the year: ₩60B. Directors and auditors: 7, paid ₩1.3B in total.

Dividends (common shares)

Largest shareholder

디더블유피홀딩스(주) holds 15.22%; with 13 related parties the group holds 33.64% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary